News & Events

lncRNA Biomarker of cardiovascular disease

lncRNA: Biomarker for diagnosing and prognosing cardiovascular diseases

Cardiovascular diseases (CVDs) are the leading cause of death globally. According to the World Health Organisation, an estimated 17.9 million people die each year from CVDs. This represents 32% of all global deaths. CVDs are responsible for twice as many death as cancer in both men and women.&nbs...

Read More
Interview with Dr Kanita Karaduzovic-Hadziabdic

Watch the interview with Dr Kanita Karađuzović-Hadžiabdić

Although lungs are the main organs involved in COVID-19, one of the major systems affected by the virus is the cardiovascular system. The presence of pre-existing cardiovascular disease increases mortality in patients with COVID-19, and cardiovascular injuries are observed in some patients with C...

Read More
First COVIRNA Annual Meeting

The first Annual Meeting takes place in Barcelona

The First Annual Meeting of the COVIRNA project took place on 11-12 November 2021 in Barcelona, Spain. The meeting was co-organised by the Luxembourg Institute of Health (LIH), the project coordinator and the Institute of Research of Hospital de la Santa Creu i Sant Pau (IR-HSCSP). It brought tog...

Read More

Early detection for improved cardiovascular health outcomes of the European population

In the spring of 2020, most European citizens, although fearful of the virus the global media was reporting on, could not possibly envisage that their lives would be so dramatically impacted and that the economic, social and environmental impacts of the COVID-19 pandemic would be so tangible. Acc...

Read More

The COVIRNA Project Coordinator, Dr Yvan Devaux, discusses the project on Radio ARA

On Thursday, 7 October 2021, from 18:30 to 20:00 CEST, Dr Yvan Devaux, the COVIRNA project coordinator, was a guest speaker at Happy Hour, a show hosted by Wendy Winn on Radio ARA. Dr Devaux spoke about the COVIRNA project and cardiovascular disease management.  Dr Devaux started by providin...

Read More
Key learnings from the COVIRNA session at the EHMA 2021 Annual Conference

The COVIRNA session at EHMA 2021 highlights the role of predictive models in improving patient outcomes

On Wednesday, 15 September from 13:30-14:45 CEST, the COVIRNA project hosted a session at the EHMA 2021 Annual Conference titled Towards personalised medicine – an innovative diagnostic tool to identify cardiovascular complications in COVID-19 patients. The session examined the benefits of person...

Read More
Interview with Dr Yvan Devaux, the COVIRNA project coordinator

Interview with the project Coordinator, Dr Yvan Devaux

To learn more about the COVIRNA project, we spoke to Dr Yvan Devaux, Coordinator of the project and Head of the Cardiovascular Research Unit at the Luxembourg Institute of Health. Dr Devaux has a background in biological sciences, with over 18 years of experience in cardiovascular disease researc...

Read More
COVIRNA session at the EHMA 2021 Annual Conference

Discover the COVIRNA session at the EHMA 2021 Annual Conference

The COVIRNA project will be participating at the EHMA 2021 Annual Conference with the session ‘Towards personalised medicine – an innovative diagnostic tool to identify cardiovascular complications in COVID-19 patients’ on Wednesday, 15 September at 13.30 CEST. EHMA 2021 Annual Conference is...

Read More
COVIRNA video

COVIRNA video: can RNA aid in predicting cardiovascular outcomes of COVID-19?

The COVIRNA project is pleased to share its official dissemination video. The video outlines the aim of the COVIRNA project to generate an innovative diagnostic tool to identify COVID-19 patients at risk of developing fatal cardiovascular complications in the context of the current pandemic, ulti...

Read More

Tacking COVID-19: the new EU-funded project COVIRNA

The COVIRNA project, led by the Luxembourg Institute of Health (LIH), is one of the 23 research projects awarded within the framework of the Horizon 2020 Call for Expression of Interest 'Innovative and rapid health-related approaches to respond to COVID-19 and to deliver quick results for society...

Read More